DOTA

Nadolol is an Antihypertensive agent indicated for the treatment of long-term management of patients with angina pectoris.


Biophore's Nadolol: Lab development complete. Tech pack available. Validations under progress. DMF by Q3, 2016.

Palbociclib is an Cyclin-Dependent Kinase Inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2. 

Sincalide is an Diagnostic Agent indicated To stimulate gallbladder, pancreatic secretion, to accelerate the transit of a barium meal through the small bowel.


Biophore's Sincalide: API Developed, Validations Planned in Q3 2016, DMF to be filed in Q1 2017.

Zofenopril is an Antihypertensive agent.

Biophore's Zofenopril: USFDA approved manufacturing facility, US DMF Filed  [ # 026446 ].

Tipiracil is an Thymidine  phosphorylase inhibitor/nucleoside metabolic inhibitor used to treatment of metastatic colorectal cancer.

Trifluridine is an Antiviral agent indicated for the treatment of of primary kerato conjunctivitis and recurrent epithelial keratitis.

DTPA is an Chelating agent

Biophore's DTPA: Stringent control on Iron content,  All impurities below 0.01

Trientinen is indicated for the treatment of  patients with Wilson's disease who are intolerant of penicillamine.

Biophore's Trientine: DMF Filed

Ultrapure synthetic cannabidiol with US DMF

Aviptadil

Biophore India Pharmaceuticals Pvt Ltd. at CPHI BCN 2023

Dr. Jagadeesh Babu Ranglsetty, Founder & CEO of BioPhore India Pharmaceuticals Pvt. Ltd., speaks With CPHI TV at CPHI Worldwide in Madrid, Spain